NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-06-24 |
2024-03 |
0 |
-0.35 |
N/A |
N/A |
2024-04-05 |
2023-12 |
0 |
-0.16 |
N/A |
N/A |
2023-11-28 |
2023-09 |
0 |
0.1 |
N/A |
N/A |
2023-08-16 |
2023-06 |
0 |
-0.44 |
N/A |
N/A |
2023-06-01 |
2023-03 |
0 |
-0.33 |
N/A |
N/A |
2023-03-22 |
2022-12 |
0 |
-0.27 |
N/A |
N/A |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Armistice Capital, LLC |
1.27M |
1.89M |
9.29% |
2023-06-29 |
Point72 Asset Management, L.P. |
100.00K |
149.00K |
0.73% |
2023-06-29 |
Meitav Investment House Ltd. |
95.00K |
141.55K |
0.70% |
2023-06-29 |
Vanguard Personalized Indexing Management, LLC |
11.19K |
16.68K |
0.08% |
2023-06-29 |
JP Morgan Chase & Company |
1.30K |
1.94K |
0.01% |
2023-09-29 |
CWM, LLC |
1000 |
710.00 |
0.01% |